Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $90

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $115 to $90.